Valuation: Quest PharmaTech Inc.

Capitalization 59.2L 43.4L 36.87L 33.76L 31.88L 41Cr 59.88L 4Cr 1.56Cr 20Cr 1.63Cr 1.59Cr 68Cr P/E ratio 2024
-1.4x
P/E ratio 2025 -3.29x
Enterprise value 67.14L 49.23L 41.83L 38.3L 36.16L 46Cr 67.92L 4.54Cr 1.77Cr 22Cr 1.85Cr 1.81Cr 77Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
82.94%
Yield 2024 *
-
Yield 2025 -
1 day+14.29%
1 month+33.33%
3 months+33.33%
Current year+14.29%
1 week 0.04
Extreme 0.035
0.04
1 month 0.02
Extreme 0.025
0.04
Current year 0.02
Extreme 0.025
0.04
1 year 0.02
Extreme 0.025
0.06
3 years 0.02
Extreme 0.015
0.1
5 years 0.02
Extreme 0.015
0.16
10 years 0.02
Extreme 0.015
0.32
Manager TitleAgeSince
Chief Executive Officer - 17/06/2004
Director of Finance/CFO - 01/01/2005
Director TitleAgeSince
Director/Board Member - 17/06/2004
Chairman - 05/07/2021
Director/Board Member - 05/07/2021
Change 5d. change 1-year change 3-years change Capi.($)
+14.29%0.00%-11.11%-46.67% 49.6L
-0.07%-0.02%-16.12%-17.14% 4.37TCr
+1.17%+7.36%+36.49%+26.91% 3.52TCr
-5.67%-1.12%+278.41%+485.50% 3.03TCr
+1.23%+12.80%+16.53%-5.24% 2.98TCr
+4.01%+1.00%+31.38%+35.66% 2.92TCr
+4.34%+7.31% - - 1.52TCr
+14.06%+7.70%+529.44%+4,525.90% 1.56TCr
-1.08%+1.69%+129.88%+110.00% 1.26TCr
-0.37%+2.83%+6.02%-8.43% 1.24TCr
Average +3.09%+3.76%+111.21%+567.39% 2.24TCr
Weighted average by Cap. +1.12%+4.09%+97.61%+419.26%

Financials

2024 2025
Net sales - -
Net income -30.18L -22.13L -18.8L -17.21L -16.26L -21Cr -30.53L -2.04Cr -79.5L -10Cr -83L -81.28L -35Cr -18.01L -13.21L -11.22L -10.27L -10L -12Cr -18.22L -1.22Cr -47.44L -5.98Cr -49.53L -48.51L -21Cr
Net Debt 3L 2L 2L 2L 2L 1.96Cr 3L 19.14L 7L 93.9L 8L 8L 3.25Cr 8L 6L 5L 5L 4L 5.49Cr 8L 53.74L 20.94L 2.64Cr 21.86L 21.41L 9.12Cr
Logo Quest PharmaTech Inc.
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. It also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Employees
-
Date Price Change Volume
07/26/07 0.0400 $ +14.29% 25,245
06/26/06 0.0350 $ -12.50% 5,000
01/26/01 0.0400 $ 0.00% 24,000
30/26/30 0.0400 $ +33.33% 2,48,000
29/26/29 0.0300 $ 0.00% 4,000